Chemical Name: N-(3,5-Dimethoxyphenyl)-N-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine. Alternate Names: JNJ-42756493
FGFR inhibitor
Molekulargewicht:
446.56
Reinheit:
>98% by HPLC NMR (Conforms)
Formulierung:
Yellow solid
Formel:
C25H30N6O2
Anwendungsbeschreibung:
Erdafitinib is a potent (IC50s = 1.2 nM FGFR1, 2.5 nM FGFR2, 3 nM FGFR3, 5.7 nM FGFR4) and selective pan-inhibitor of FGFR.1 Alone and in combination with PD-1 blockade it increased T-cell infiltration, decreased Treg cells, and down-regulation of PD-L1 expression leading to enhanced antitumor immunity and survival in a lung cancer model.2 Erdafitinib elicited antitumor responses through direct inhibition of oncogenic signaling as well as normalization of the tumor microenvironment in various cancer models including bladder (for which it is FDA approved)3, triple negative breast4, and pancreatic5.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
